Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR — Clinical Trial Site

41 Registered trials

19 Currently recruiting

Organisation

Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR

Location

Nuertingen, Germany

Identifier

ORG-100040303

Address

Steinengrabenstrasse 17, 72622, Germany

Departments

#1802: Studienpraxis Urologie
2605
N/A
NA
not applicable
Praxis für Urologie
Private research practice
Studienpraxis fuer Urologie
Studienpraxis Urologie
Studienpraxis Urologie Nürtingen
Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR
Studienzentrum
Urologie
Urology
Uroncology

Clinical trials at this site (41)

Search interface

A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Carcinoma, Transitional Cell 5
A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting

2025-521327-67-00 Metastatic Castration-Resistant Prostate Cancer 4 2026-04-13
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 10 2024-10-02
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t… Recruiting

2022-500461-28-06 High-Risk Metastatic Hormone-Sensitive Prostate Cancer 5 2022-09-15
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Metastatic castration resistant prostate cancer 5 2026-03-24
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-522713-29-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2026-03-12
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af… Recruiting

2025-522400-24-00 Metastatic urothelial cancer 10 2026-01-27
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting

2024-517653-27-00 Prostate Cancer 4 2025-12-17
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting

2024-519493-39-00 High-risk Non-muscle-invasive Bladder Cancer with Susce 5 2025-12-09
Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-520927-26-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-11-24
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Metastatic hormone-sensitive prostate cancer 4 2025-10-08
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Metastatic Castration-Resistant Prostate Cancer 5 2025-06-23
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Recruiting

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) an… Recruiting

2024-512900-20-00 Non-muscle invasive bladder cancer (NMIBC) 7 2025-01-30
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting

2023-506987-15-00 Metastatic Castration-Resistant Prostate Cancer 9 2016-11-17
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab… Ended

2024-511650-50-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-01-17
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23